ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
January 18, 2022The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19... -
Daiichi Sankyo Presents Positive Results from LIXIANA Study
September 05, 2019Daiichi Sankyo announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name LIXIANA®▼) plus a P2Y12 inhibitor... -
Idorsia's selatogrel hits goals in phase 2 cardiovascular trials
December 25, 2018Idorsia's P2Y12 receptor antagonist selatogrel has significantly inhibited platelet aggregation in two phase 2 trials. The primary endpoint successes in patients with ....
Pharma Sources Insight January 2025
